The Relationship Between Immune Infiltration And Treatment Prognosis In Triple-Negative Breast Cancer Tumor Microenvironment

Objective:Using the methods of bioinformatics analysis,cell co-culture and Western Blot,to find the immune infiltration components with significant differences in triple-negative breast cancer(TNBC)cancer and adjacent tissue,PCR and non-PCR,and treatment prognosis,and to explore its relationship with triple-negative breast cancer(TNBC).The relationship between cancer treatment prognosis and the search for potential immunotherapy targetsMethod:The 12 gene expression chips related to TNBC were obtained by searching the GEO database of NCBI,and were divided into three groups related to TNBC cancer and adjacent tissue,PCR and non-PCR,and treatment prognosis for differential gene enrichment analysis.The expressed genes were scored for immune infiltration,and SPSS software was used to find the immune infiltration components with common differences.Macrophages and TNBC cells were co-cultured by Transwell,stimulated with different chemotherapeutic drugs,and further verified by Western Blot after protein extraction.Result:A common differential gene,CNOT7,was found in five neoadjuvant gene chips,and its high expression was associated with better PCR rates,and Siglec(sialic acid-binding immunoglobulin-like lectin)was also found to affect PCR in TNBC patients rates,both of which may represent potential therapeutic targets.Immune infiltration analysis showed that M1 macrophages and CD8+ T cells could improve the PCR rate in patients with neoadjuvant therapy,and the expression of macrophages in TNBC tumor tissues was significantly higher than that in non-tumor tissues,patients with high mononuclear cell infiltration had lower mortality and relapse rates.The results of cell experiments confirmed that TNBC cells can inhibit M1 macrophages and induce their transformation to M2 macrophages.The expression of M1 macrophages in TNBC cells stimulated by anthracyclines and cisplatin was significantly increased..Conclusion:1.Mononuclear macrophages in the tumor microenvironment can improve the PCR rate of neoadjuvant therapy in TNBC patients and reduce recurrence and mortality.2.M1 macrophages can improve the neoadjuvant effect of anthracyclines and cisplatin,and these two drugs can in turn improve the antitumor effect of M1 macrophages.In addition,paclitaxel drugs can inhibit the differentiation of M0 macrophages in TAM.3.TNBC cells can inhibit the transformation of M0 to M1-type macrophages and promote their transformation to M2-type macrophages,thereby inhibiting the body’s anti-tumor response and obtaining immune escape.